Drug Class: DPP-4 Inhibitor + Biguanide Antidiabetic Combination | Form: Extended-Release Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered
What is Tagipmet XR 100/500mg Tablet? Tagipmet XR 100/500mg contains the full standard Sitagliptin dose of 100mg combined with Metformin Hydrochloride 500mg in an extended-release formulation — providing maximum DPP-4 inhibition alongside a gradual Metformin starting dose in a single convenient tablet. This combination is particularly suited to patients with normal kidney function transitioning from Sitagliptin 100mg monotherapy who require the addition of Metformin for better glycaemic control — or patients starting dual combination therapy where gradual Metformin uptitration from 500mg is clinically preferred to minimise gastrointestinal side effects before escalation to the 100/1000mg maintenance dose. The XR mechanism releases Metformin slowly — significantly reducing gastrointestinal side effects while Sitagliptin at its full 100mg dose provides complete DPP-4 inhibition for maximum incretin-mediated glucose control.
What is Tagipmet XR 100/500mg Used For?
- Type 2 diabetes — full Sitagliptin dose combination with starting Metformin dose (ذیابیطس ٹائپ 2 میں مکمل سیتاگلپٹن خوراک کے ساتھ میٹفارمن کا آغاز)
- Step-up from Sitagliptin 100mg monotherapy — adding Metformin at starting dose when Sitagliptin alone insufficient
- Initial dual combination therapy — starting patients on both medicines simultaneously at conservative Metformin dose
- Uptitration phase — starting combination before stepping up to 100/1000mg maintenance dose
- Type 2 diabetes with normal kidney function — full 100mg Sitagliptin dose appropriate for normal renal clearance (گردوں کی معمول کی کارکردگی میں ذیابیطس ٹائپ 2)
- Simplifying regimen — replacing separate Sitagliptin 100mg and Metformin XR 500mg tablets
How Does it Work? Sitagliptin 100mg achieves complete DPP-4 inhibition — maintaining maximally elevated active GLP-1 and GIP incretin levels to stimulate full glucose-dependent insulin secretion from pancreatic beta cells and maximally suppress glucagon from alpha cells. This glucose-dependent mechanism provides the strongest Sitagliptin glycaemic effect while maintaining its inherently low hypoglycaemia risk profile. Metformin 500mg begins reducing hepatic glucose production through gluconeogenesis and glycogenolysis inhibition — providing immediate fasting glucose benefit while allowing gastrointestinal tolerance to develop before dose escalation to 1000mg. The XR formulation releases Metformin 500mg gradually — ensuring smooth absorption with minimal peak gastrointestinal drug concentrations that cause the nausea and diarrhoea associated with immediate-release formulations.
Dosage and Administration
⚠️ Swallow whole — never crush, break, or chew extended-release tablet. Take with evening meal for best tolerability. Stop before iodinated contrast imaging — lactic acidosis risk with Metformin component. Monitor kidney function regularly — full 100mg Sitagliptin dose appropriate for normal kidney function only. Plan to uptitrate Metformin to 1000mg under diabetologist guidance.
| Indication | Usual Adult Dose | Frequency | Notes |
|---|---|---|---|
| Initial dual combination therapy | 100mg/500mg | Once daily with evening meal | Starting dose — plan uptitration |
| Step-up from Sitagliptin 100mg alone | 100mg/500mg | Once or twice daily with meals | Adding Metformin at starting dose |
| Uptitration phase | 100mg/500mg | Twice daily with meals | Before stepping up to 100/1000mg |
| Replacing separate tablets | 100mg/500mg | As prescribed | Equivalent to separate 100mg + 500mg tablets |
Active Ingredients
| Ingredient | Strength |
|---|---|
| Sitagliptin Phosphate Monohydrate | 100mg (as Sitagliptin) |
| Metformin Hydrochloride | 500mg (Extended-Release) |
Who Should NOT Take Tagipmet XR 100/500mg?
- Allergy to Sitagliptin, Metformin, or any component of the tablet
- Type 1 diabetes mellitus — not indicated
- Diabetic ketoacidosis — requires urgent insulin therapy
- Moderate to severe kidney impairment — GFR below 45ml/min; Metformin contraindicated and Sitagliptin requires dose reduction to 50mg or 25mg
- Severe liver impairment — lactic acidosis risk with Metformin
- Acute conditions causing dehydration or tissue hypoxia — heart failure, respiratory failure, recent heart attack
- History of pancreatitis — Sitagliptin associated with pancreatitis risk
- Alcohol dependence — greatly increases lactic acidosis risk
- Planned iodinated contrast imaging — stop before procedure
- Pregnancy and breastfeeding — insulin preferred
- Children under 18 years
Side Effects
Common: Mild nausea, mild stomach discomfort, mild diarrhoea — significantly reduced by XR formulation; taking with evening meal further minimises effects. Mild headache, mild upper respiratory symptoms — generally very well tolerated particularly at this lower 500mg Metformin starting dose.
Serious — Stop and seek emergency help immediately: Lactic acidosis — severe muscle pain, difficulty breathing, severe stomach pain, extreme weakness and dizziness (فوری ہسپتال جائیں — یہ طبی ہنگامی صورتحال ہے), acute pancreatitis — severe persistent upper abdominal pain radiating to back (پیٹ میں شدید درد — فوری مدد لیں), severe allergic reaction — sudden swelling of face or throat with difficulty breathing (فوری ہسپتال جائیں), Stevens-Johnson syndrome — widespread blistering and peeling skin (فوری مدد لیں), significant disabling joint pain — severe arthralgia (جوڑوں کا شدید درد — ڈاکٹر کو بتائیں), heart failure worsening with breathlessness and ankle swelling (فوری مدد لیں), hypoglycaemia when combined with sulphonylurea or insulin (بلڈ شوگر کا گرنا — فوری میٹھا کھائیں).
Drug Interactions
| Medicine | Interaction |
|---|---|
| Iodinated contrast media | Stop Tagipmet XR minimum 48 hours before contrast procedure — restart only after kidney function confirmed normal post-procedure |
| Sulphonylureas (Glibenclamide, Glimepiride) | Significantly increased hypoglycaemia risk — sulphonylurea dose reduction required when adding this combination |
| Insulin | Increased hypoglycaemia risk — careful insulin dose adjustment under specialist supervision |
| Alcohol (شراب) | Increases lactic acidosis risk with Metformin and causes unpredictable blood sugar changes — avoid completely |
| Corticosteroids (Prednisolone) | Significantly raise blood glucose — monitor blood sugar closely during steroid courses |
| Diuretics (Furosemide, Thiazides) | Dehydration increases lactic acidosis risk — monitor kidney function and fluid status |
| ACE inhibitors / ARBs | May cause acute kidney deterioration — reduced renal clearance increases Metformin accumulation risk |
| Cimetidine | Significantly increases Metformin blood levels — lactic acidosis risk; monitor |
| Beta-blockers | Mask hypoglycaemia warning signs — important when combined with sulphonylurea or insulin |
| Digoxin | Sitagliptin slightly increases Digoxin levels — monitor in patients on both medicines |
Storage: Store below 25°C in a cool, dry place. Protect from moisture and direct sunlight. Swallow whole — never break, crush, or chew. Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں). Do not use after expiry date.
FAQs
Q: What is the difference between Tagipmet XR 100/500mg and Tagipmet XR 50/500mg? Both contain Metformin 500mg — the difference is the Sitagliptin dose. Tagipmet XR 100/500mg contains the full standard 100mg Sitagliptin dose for patients with normal kidney function requiring maximum DPP-4 inhibition. Tagipmet XR 50/500mg contains the dose-adjusted 50mg Sitagliptin for patients with moderate kidney impairment where the full 100mg dose accumulates unsafely.
Q: Why is Tagipmet XR 100/500mg considered a starting combination before escalating to 100/1000mg? Starting at the lower 500mg Metformin dose allows the gastrointestinal system to adapt to Metformin gradually — reducing the nausea and diarrhoea that commonly cause early treatment discontinuation. Once the 500mg dose is well tolerated after 4 to 8 weeks your diabetologist will typically uptitrate to the 100/1000mg maintenance dose for maximum glycaemic benefit.
Q: Is Tagipmet XR 100/500mg suitable for patients with any degree of kidney disease? Only for patients with normal to mildly reduced kidney function — GFR above 60ml/min ideally, with caution between 45 and 60ml/min. Both components require dose adjustment or cessation as kidney function declines — Metformin must be stopped at GFR below 45ml/min and Sitagliptin must be reduced to 50mg between GFR 30 and 50ml/min. Regular kidney function monitoring throughout treatment is essential.
Medical Disclaimer: This information is for general awareness only and does not replace medical advice. Always consult a qualified doctor or pharmacist before taking any prescription medicine.